Archives of the
Turkish Society of Cardiology
Invited review

Ranolazin: mechanism of antianginal effects

Archives of the Turkish Society of Cardiology 2016; 44: Supplement S8-S12
DOI: 10.5543/tkda.2016.72626
Read: 764 Downloads: 129 Published: 24 September 2021

Ranolazin is indicated for the control of angina in patients with chronic stable coronary artery disease. Born as a “metabolic modulator”, ranolazine is now considered to be a “late sodium current blocker”. This review tries to summarize the mechanism of antianginal effects of ranolazine.

Files
TURKISH
ISSN 1016-5169 EISSN 1308-4488